BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Khayat H, Kamal EM, Yakoot M, Gawad MA, Kamal N, El Shabrawi M, Sameh Y, Haseeb A, Fouad Y, Attia D. Effectiveness of 8-week sofosbuvir/Ledipasvir in the adolescent chronic hepatitis C-infected patients. Eur J Gastroenterol Hepatol. 2019;31:1004-1009. [PMID: 30676473 DOI: 10.1097/meg.0000000000001360] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Reference Citation Analysis]
2 Fu Z, Dong C, Ge Z, Wang C, Zhang Y, Shen C, Li J, Zhu C, Wang Y, Huang P, Yue M. High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis. Front Med (Lausanne) 2021;8:608760. [PMID: 34169081 DOI: 10.3389/fmed.2021.608760] [Reference Citation Analysis]
3 Pokorska-śpiewak M, Dobrzeniecka A, Marczyńska M. The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C. Viruses 2022;14:474. [DOI: 10.3390/v14030474] [Reference Citation Analysis]
4 Pokorska-Śpiewak M, Dobrzeniecka A, Aniszewska M, Marczyńska M. Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project. J Clin Med 2021;10:4176. [PMID: 34575286 DOI: 10.3390/jcm10184176] [Reference Citation Analysis]